Table 2.
Independent determinants of time to CVD and all-cause mortality in FDS primary prevention subjects
| HR (95% CI) | P value | |
|---|---|---|
| Cardiovascular mortality | ||
| Age (increase of 10 years) | 3.09 (2.27–4.21) | <0.001 |
| Diabetes duration (increase of 5 years) | 1.27 (1.09–1.49) | 0.003 |
| Not fluent in English | 0.17 (0.07–0.47) | 0.001 |
| BMI (increase of 1 kg/m2) | 0.92 (0.87–0.97) | 0.002 |
| ln(urine ACR)* | 1.21 (1.02–1.44) | 0.034 |
| Regular aspirin use | 0.30 (0.09–0.95) | 0.041 |
| All-cause mortality | ||
| Age (increase of 10 years) | 2.15 (1.76–2.62) | <0.001 |
| Male sex | 1.47 (1.06–2.03) | 0.022 |
| Southern European ethnicity | 0.63 (0.40–0.98) | 0.041 |
| BMI (increase of 1 kg/m2) | 0.93 (0.90–0.97) | <0.001 |
| Lipid-modifying therapy | 0.30 (0.11–0.82) | 0.018 |
| ln(urinary ACR)* | 1.36 (1.21–1.52) | <0.001 |
| Peripheral neuropathy | 1.79 (1.27–2.53) | 0.001 |
| Regular aspirin use | 0.53 (0.28–0.98) | 0.044 |
The most parsimonious models are shown with HRs (95% CI). The HRs for regular aspirin use are those after adjustment for the significant variables in the models.
*A 2.72-fold increase in ACR or triglycerides corresponds to an increase of 1 in ln(ACR) or ln(triglycerides), respectively.